Local Prostate Radiation Therapy and Symptomatic Local Events in De Novo Metastatic Prostate Cancer

Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3

Parker, 2022, Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial, PLoS Med, 19, 10.1371/journal.pmed.1003998

Anast, 2007, Managing the local complications of locally advanced prostate cancer, Curr Urol Rep, 8, 211, 10.1007/s11934-007-0008-6

Otnes, 1995, The burden of prostate cancer from diagnosis until death, Br J Urol, 76, 587, 10.1111/j.1464-410X.1995.tb07783.x

Ranasinghe, 2020, Patterns of metastases of prostatic ductal adenocarcinoma, Cancer, 126, 3667, 10.1002/cncr.32957

Cameron, 2015, Palliative pelvic radiotherapy for symptomatic incurable prostate cancer—a prospective multicenter study, Radiother Oncol, 115, 314, 10.1016/j.radonc.2015.05.021

Hindson, 2007, Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancer, Australas Radiol, 51, 584, 10.1111/j.1440-1673.2007.01897.x

White, 2015, Efficacy of high-dose palliative radiotherapy for localised, castration-resistant prostate cancer, Clin Oncol, 27, 16, 10.1016/j.clon.2014.09.013

Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747

Park, 2012, Immortal time bias: A frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy, Int J Radiat Oncol, 83, 1365, 10.1016/j.ijrobp.2011.10.025

Terada, 2020, Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer, BJUI Compass, 1, 165, 10.1002/bco2.35